Tumor Mutational Burden

CHICAGO — Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy.

Cancers with high vs. low tumor mutational burden appeared significantly associated with improved clinical outcomes among patients treated with immune checkpoint inhibitors, according to data published in JAMA Network Open.

Nivolumab plus ipilimumab induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Pembrolizumab demonstrated antitumor activity among women with heavily pretreated metastatic breast cancer characterized by high tumor mutational burden, according to phase 2 results from the TAPUR basket study.

Tumor mutational burden predicted immune checkpoint inhibitor response among women, but not men, with melanoma, according to findings presented during the virtual American Association for Cancer Research Annual Meeting.

Tumor mutational burden predicted immunotherapy response for some, but not all, cancer types, according to study results published in Annals of Oncology.

Molecular oncology is a rapidly evolving field with exciting results.

Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy.

The FDA approved a second biomarker-based indication for the anti-PD-1 therapy pembrolizumab.